FINWIRES · TerminalLIVE
FINWIRES

BOM:500124

9 stories mentioning BOM:500124Updated 4d ago

Every FINWIRES story that references BOM:500124, newest first.

What are analysts saying about BOM:500124?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on BOM:500124?

Asia

Dr. Reddy's Enters Agreement to Bring Takeda's Dengue Vaccine to India

Dr. Reddy's Laboratories (BOM:500124, NSE:DRREDDY) signed a marketing and distribution agreement with Takeda Biopharmaceuticals India to bring the Qdenga dengue vaccine to India, according to a same-day filing with the bourse.Dr. Reddy's will handle private market sales, while Takeda Biopharmaceuticals, a unit of Japan-listed Takeda Pharmaceutical (TYO:4502), will manufacture, import and oversee public market distribution.The agreement follows Indian regulators' July clearance of Qdenga for individuals aged 4 to 60, making it the country's first approved dengue vaccine, the company said.Dr. Reddy's shares were last up around 2% in recent trade.

BOM:500124NSE:DRREDDYTYO:4502
Asia

Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2%

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has signed a licensing pact with U.S. drugmaker Gilead Sciences for the once-a-year HIV prevention drug lenacapavir, the company confirmed in a Friday filing with the bourse.The company disclosed the update after an Economic Times report on Thursday said the Indian pharma giant secured a royalty-free, non-exclusive, voluntary license for the HIV drug.Shares are up roughly 2% in morning trading on the BSE and NSE.

BOM:500124NSE:DRREDDY
Asia

Gland Pharma Names Dr. Reddy's Executive as CEO

Gland Pharma (NSE:GLAND, BOM:543245) appointed Deepak Sapra as its new chief executive officer, effective Nov. 16.Sapra currently serves as CEO of API and Services at Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124), according to an Indian bourse filing on Friday.Shares of the company rose over 1% in recent trade.

BOM:500124BOM:543245NSE:DRREDDYNSE:GLAND
Asia

Elara Securities India Downgrades Dr. Reddy's Laboratories to Reduce From Accumulate; Price Target is INR1,283

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has an average rating of hold and mean price target of 1,355.97 Indian rupees, according to analysts polled by FactSet.

BOM:500124NSE:DRREDDY
Asia

Dr. Reddy's Laboratories Delays Semaglutide Supplies After Batch Quality Issue; Shares Plummet 6%

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) said commercial supplies of its semaglutide product will be delayed for some time after certain batches failed quality specifications due to an issue linked to the active pharmaceutical ingredient.The company is probing the root cause and taking corrective measures, according to an Indian bourse filing on Thursday. There is no impact on patient safety or existing global regulatory filings, the company said in the filing.Shares of the company plunged 6% in recent trade.

BOM:500124NSE:DRREDDY
Asia

Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,740 From INR1,600, Keeps at Buy

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has an average rating of hold and mean price target of 1,335.44 Indian rupees, according to analysts polled by FactSet.

BOM:500124NSE:DRREDDY
Asia

Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, the Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/pen (in 1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).Dr. Reddy's shares were down nearly 1% in recent trade.

BOM:500124BOM:544292NSE:DRREDDYNSE:ONESOURCE
Asia

Update: Dr. Reddy's Laboratories Gets Regulatory Nod to Sell Semaglutide Injection in Canada

Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).The company's shares were down nearly 1% in recent trade.

BOM:500124BOM:544292NSE:DRREDDYNSE:ONESOURCE
Asia

Dr. Reddy's Laboratories Board to Consider Final Dividend for Fiscal 2026

Dr. Reddy's Laboratories' (NSE:DRREDDY, BOM:500124) board will meet on May 12 to consider the payment of a final dividend for fiscal 2026 ended March 31, according to an Indian bourse filing on Thursday.

BOM:500124NSE:DRREDDY

Track with the FINWIRES app suite

FolioX
FolioX
Track BOM:500124 in your portfolio
WheelAI
WheelAI
Analyze BOM:500124 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on BOM:500124